Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Hypoglycemia was reported more commonly with the use of sitagliptin in combination with a sulfonylurea, a class of medicines known to cause hypoglycemia. When used in combination with a ...